Sezary SyndromeSymptoms, Doctors, Treatments, Advances & More
Learn About Sezary Syndrome
Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform.
The cause of Sézary syndrome is unknown. Most affected individuals have one or more chromosomal abnormalities, such as the loss or gain of genetic material. These abnormalities occur during a person's lifetime and are found only in the DNA of cancerous cells. Abnormalities have been found on most chromosomes, but some regions are more commonly affected than others. People with this condition tend to have losses of DNA from regions of chromosomes 10 and 17 or additions of DNA to regions of chromosomes 8 and 17. It is unclear whether these alterations play a role in Sézary syndrome, although the tendency to acquire chromosomal abnormalities (chromosomal instability) is a feature of many cancers. It can lead to genetic changes that allow cells to grow and divide uncontrollably.
Sézary syndrome is a rare condition, although its prevalence is unknown. It is the second most common form of cutaneous T-cell lymphoma after mycosis fungoides, accounting for approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma.
The inheritance pattern of Sézary syndrome has not been determined. This condition occurs in people with no history of the disorder in their family and is not thought to be inherited in most cases.
CUIMC/Herbert Irving Pavilion
Larisa Geskin is an Oncologist practicing medicine in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.
Christiane Querfeld, M.D., PH.D.
Christiane Querfeld is a Dermatologist practicing medicine in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.
Penn Dermatology Perelman
Alain Rook is a Dermatologist practicing medicine in Philadelphia, Pennsylvania. Dr. Rook is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome. Dr. Rook is board certified in Dermatology, 1991, Nephrology, 1980, and Internal Medicine, 1979. Dr. Rook is currently accepting new patients.
Summary: This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy...
Summary: The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Published Date: May 17, 2021
Published By: National Institutes of Health